Indivior Pharmaceuticals (INDV) Free Cash Flow (2024 - 2026)

Indivior Pharmaceuticals' Free Cash Flow history runs 3 years deep, the most recent figure standing at -$29.0 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 141.43% year-over-year to -$29.0 million; the TTM figure through Mar 2026 stood at -$192.0 million (down 265.52% YoY), while the FY2025 annual figure was -$93.0 million, down 1428.57% from the prior year.
• Free Cash Flow was -$29.0 million for Q1 2026 at Indivior Pharmaceuticals, up from -$245.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $141.0 million in Q2 2025 to a low of -$245.0 million in Q4 2025.
• Historically, Free Cash Flow has averaged -$12.8 million across 3 years, with a median of -$29.0 million in 2026.
• Biggest YoY gain for Free Cash Flow was 279.49% in 2025; the steepest drop was 1080.0% in 2025.
• A 3-year view of Free Cash Flow shows it stood at -$33.0 million in 2024, then plunged by 642.42% to -$245.0 million in 2025, then jumped by 88.16% to -$29.0 million in 2026.
• The last three Free Cash Flow figures came in at -$29.0 million (Q1 2026), -$245.0 million (Q4 2025), and -$59.0 million (Q3 2025), per Business Quant data.